Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): A proof-of-principle clinical trial with ribavirin

Blood

Volumn 114, Issue 2, 2009, Pages 257-260

  Assouline, Sarit ^a   Culjkovic, Biljana ^b   Cocolakis, Eftihia ^a   Rousseau, Caroline ^a   Beslu, Nathalie ^b   Amri, Abdellatif ^b   Caplan, Stephen ^a   Leber, Brian ^c   Roy, Denis Claude ^d   Miller Jr , Wilson H ^a   Borden, Katherine L B ^b  

^a MCGILL UNIVERSITY   (Canada)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INITIATION FACTOR 4E; RIBAVIRIN;

ABSENCE OF SIDE EFFECTS; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; CYTOPLASM; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; REMISSION; TREATMENT RESPONSE; DRUG ANTAGONISM; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; EUKARYOTIC INITIATION FACTOR-4E; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RIBAVIRIN;

EID: 67651089847     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-02-205153     Document Type: Article

References (17)

1. Topisirovic I, Guzman ML, McConnell MJ, et al. Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis. Mol Cell Biol. 2003;23:8992-9002. (Pubitemid 37499790)
2. Ruggero D, Pandolfi PP. Does the ribosome translate cancer? Nat Rev Cancer. 2003;3:179-192. (Pubitemid 37328870)
3. Graff JR, Zimmer SG. Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin Exp Metastasis. 2003;20:265-273.
4. Culjkovic B, Topisirovic I, Borden KL. Controlling gene expression through RNA regulons: the role of the eukaryotic translation initiation factor eIF4E. Cell Cycle. 2007;6:65-69. (Pubitemid 46173883)
5. Cohen N, Sharma M, Kentsis A, Perez JM, Strudwick S, Borden KL. PML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA. EMBO J. 2001;20:4547-4559. (Pubitemid 32772048)
6. Topisirovic I, Culjkovic B, Cohen N, Perez JM, Skrabanek L, Borden KL. The proline-rich home-odomain protein, PRH, is a tissue-specific inhibitor of eIF4E-dependent cyclin D1 mRNA transport and growth. EMBO J. 2003;22:689-703. (Pubitemid 36193613)
7. Kentsis A, Volpon L, Topisirovic I, et al. Further evidence that ribavirin interacts with eIF4E. RNA. 2005;11:1762-1766. (Pubitemid 41720025)
8. Kentsis A, Topisirovic I, Culjkovic B, Shao L, Borden KL. Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap. Proc Natl Acad Sci U S A. 2004;101:18105-18110. (Pubitemid 40054081)
9. Tan K, Culjkovic B, Amri A, Borden KL. Ribavirin targets eIF4E dependent Akt survival signaling. Biochem Biophys Res Commun. 2008;375:341-345.
10. Culjkovic B, Tan K, Orolicki S, Amri A, Meloche S, Borden KL. The eIF4E RNA regulon promotes the Akt signaling pathway. J Cell Biol. 2008;181:51-63.
11. Koren G, King S, Knowles S, Phillips E. Ribavirin in the treatment of SARS: a new trick for an old drug? CMAJ. 2003;168:1289-1292. (Pubitemid 36609908)
12. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21: 4642-4649.
13. Topisirovic I, Kentsis A, Perez JM, Guzman ML, Jordan CT, Borden KL. Eukaryotic translation initiation factor 4E activity is modulated by HOXA9 at multiple levels. Mol Cell Biol. 2005;25:1100-1112. (Pubitemid 40165816)
14. Topisirovic I, Siddiqui N, Lapointe VL, et al. Molecular dissection of the eukaryotic initiation factor 4E (eIF4E) export-competent RNP. EMBO J. 2009;28:1087-1098.
15. Graff JR, Konicek BW, Vincent TM, et al. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest. 2007;117:2638-2648.
16. DeFatta RJ, Nathan CO, De Benedetti A. Anti-sense RNA to eIF4E suppresses oncogenic properties of a head and neck squamous cell carcinoma cell line. Laryngoscope. 2000;110:928-933. (Pubitemid 30368633)
17. Dong K, Wang R, Wang X, et al. Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells. Breast Cancer Res Treat. 2009;113:443-456.